Clinical Trial Update: Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update shows a tyrosine kinase inhibition approach for eosinophilic myeloid neoplasms, including hypereosinophilic syndrome, is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Myeloid Neoplasm
• Hypereosinophilic Syndrome

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Eosinophilic Myeloid Neoplasm, Hypereosinophilic Syndrome | Phase 2 | Status: ACTIVE_NOT_RECRUITING